CVS HEALTH CORPORATION |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 61.1 USD | +0.14% |
|
-0.03% | -22.73% |
| 06-18 | Rate of US uninsured to rise to 8.9% in the next decade, Congressional Budget Office says | RE |
| 06-18 | Amazon Pharmacy expands $5 monthly subscription to Medicare patients | RE |
Summary
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- With a P/E ratio at 10.75 for the current year and 9.09 for next year, earnings multiples are highly attractive compared with competitors.
- The stock, which is currently worth 2024 to 0.34 times its sales, is clearly overvalued in comparison with peers.
- The company appears to be poorly valued given its net asset value.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- This company will be of major interest to investors in search of a high dividend stock.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Weaknesses
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company sustains low margins.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -22.73% | 76.59B | B- | ||
| +24.87% | 89.22B | C+ | ||
| +3.24% | 26.87B | C+ | ||
| -8.98% | 17.41B | B | ||
| +1.14% | 17.25B | A- | ||
| -0.33% | 15.25B | A- | ||
| +80.96% | 13.43B | C+ | ||
| +73.36% | 13.26B | C- | ||
| -24.74% | 13.22B | - | - | |
| +24.26% | 12.75B | B- |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- CVS Stock
- Ratings CVS Health Corporation
